Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label extension study of Varoglutamstat to patients who have been treated under VIVIAD or VIVA-MIND protocols

Trial Profile

An open label extension study of Varoglutamstat to patients who have been treated under VIVIAD or VIVA-MIND protocols

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Varoglutamstat (Primary)
  • Indications Alzheimer's disease; Cognition disorders; Mild cognitive impairment
  • Focus Therapeutic Use
  • Acronyms VIVALONG

Most Recent Events

  • 24 Apr 2024 According to a Vivoryon Therapeutics media release, In line with the Companys cost reduction measures and given the developments of VIVIAD and VIVA-MIND, Vivoryon has decided to stop VIVALONG OLE study preparation activities
  • 26 Oct 2023 According to a Vivoryon Therapeutics media release, the company has commenced preparations for an open-label extension (OLE) study I July 2023, to provide a long-term treatment option to patients after completion of treatment under the VIVIAD or VIVA-MIND protocol.
  • 18 Jul 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top